Seres Therapeutics, Inc. (MCRB): Valuation
TTM figures as of June 30, 2026
Seres Therapeutics, Inc. trades at a -101.93% free-cash-flow yield. That FCF yield is higher than 7% of its own month-end history back to 2015.
Earnings yield -44.64%.
135 month-end valuation observations are on file, starting June 2015.
Sector comparison uses 2682 Healthcare names.
Frequently asked questions
Is MCRB cheap versus its own history?
Seres Therapeutics, Inc. trades at a -101.93% free-cash-flow yield. That FCF yield is higher than 7% of its own month-end history back to 2015.
What is MCRB's free-cash-flow yield?
Seres Therapeutics, Inc. currently yields -101.93% of market cap as trailing free cash flow.
Where do these valuation figures come from?
Yields and quality metrics are computed from the same SEC TTM figures as the financials page, against the live market cap. Historical bands reconstruct month-end market cap from split-adjusted closes and the share count in the units it was filed, then divide by those dollar totals. Nothing here is a third-party estimate.